This inventor holds 1 USPTO granted patent, plus 1 CIPO patent. Top assignee: Johnson & Johnson Clinical Diagnostics, Inc.. Active years: 2000.
Company Filing History:
Years Active: 2000
Title: Andrew Jonathan Beard: Innovator in Antenatal Risk Assessment
Introduction
Andrew Jonathan Beard is a notable inventor based in High Wycombe, GB. He has made significant contributions to the field of antenatal screening, particularly in assessing the risk of chromosomal abnormalities in unborn children. His innovative approach has the potential to improve prenatal care and outcomes for expectant mothers.
Latest Patents
Beard holds a patent for a method of antenatal risk assessment screening for pregnancy abnormalities. This patent, titled "Antenatal risk assessment screening for pregnancy abnormalities," focuses on using dimeric inhibin concentration to determine the risk of a woman carrying an unborn child affected by chromosomal abnormalities, such as Down Syndrome. The method involves measuring body fluid taken from a pregnant woman and comparing the levels of specific markers with reference values from women carrying fetuses with chromosomal abnormalities and those with normal fetuses. Additionally, the free beta subunit of human chorion gonadotropin serves as a second marker. The apparatus for this method includes a computer designed to compare the described values.
Career Highlights
Throughout his career, Andrew Jonathan Beard has worked with prominent companies in the diagnostics field. He has been associated with Johnson & Johnson Clinical Diagnostics, Inc. and Ortho-Clinical Diagnostics, Inc. His experience in these organizations has contributed to his expertise in medical diagnostics and innovation.
Collaborations
Beard has collaborated with notable professionals in his field, including Adrian Charles Dawkes and Christopher John Davies. These collaborations have likely enriched his work and contributed to advancements in antenatal screening technologies.
Conclusion
Andrew Jonathan Beard's contributions to antenatal risk assessment represent a significant advancement in prenatal care. His innovative methods and dedication to improving health outcomes for mothers and their unborn children are commendable.